Literature DB >> 11323578

Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study.

R E Sampliner1, D Faigel, M B Fennerty, D Lieberman, A Ippoliti, K Lewin, W M Weinstein.   

Abstract

BACKGROUND: Barrett's esophagus is a metaplastic change in the esophageal lining with an increased risk for adenocarcinoma. Multiple endoscopic techniques have been applied in an effort to reverse Barrett's. This is a multicenter trial defining the efficacy and safety of multipolar electrocoagulation combined with high-dose acid inhibition.
METHODS: Patients with a 2- to 6-cm segment of Barrett's esophagus without dysplasia were enrolled at 3 centers. They were treated with omeprazole 40 mg twice daily and then with up to 6 sessions with electrocoagulation aimed at eliminating all the endoscopically apparent Barrett's. Four quadrant large-capacity biopsies every 2 cm were centrally assessed for residual intestinal metaplasia.
RESULTS: Fifty-eight patients reached the endpoint of failure of visual reversal of Barrett's after 6 treatment sessions or a 6-month follow-up after the last session. Eighty-five percent had visual reversal and 78% both visual and histologic reversal. Four patients had histologic evidence of residual intestinal metaplasia. Transient esophageal symptoms were common. One patient developed a stricture requiring dilation and one required overnight hospitalization for chest pain.
CONCLUSIONS: The majority of patients with 2 to 6 cm of nondysplastic Barrett's esophagus can be safely reversed with this combination therapy. Long-term follow-up will be necessary to document the durability of the new squamous epithelium.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323578     DOI: 10.1067/mge.2001.114418

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  24 in total

1.  [Barrett esophagus: ablative methods of treatment].

Authors:  M Jung; C Ell
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

2.  [Laparoscopic fundoplication. Indications and results].

Authors:  K H Fuchs; H Feussner
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

3.  Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer.

Authors:  R C Fitzgerald
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 4.  Barrett's esophagus.

Authors:  Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

5.  Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Authors:  Panteleimon Kountourakis; Jaffer A Ajani; Marta Davila; Jeffrey H Lee; Manoop S Bhutani; Julie G Izzo
Journal:  Gastrointest Cancer Res       Date:  2012-03

Review 6.  Barrett's esophagus--Who, how, how often and what to do with dysplasia?

Authors:  Lawrence C Hookey
Journal:  Can J Gastroenterol       Date:  2006-07       Impact factor: 3.522

Review 7.  Barrett's oesophagus: the new endoscopic modalities have a future.

Authors:  J Deviere
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

8.  Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus.

Authors:  Rami J Badreddine; Ganapathy A Prasad; Kenneth K Wang; Louis M Wong Kee Song; Navtej S Buttar; Kelly T Dunagan; Lori S Lutzke; Lynn S Borkenhagen
Journal:  Gastrointest Endosc       Date:  2009-12-03       Impact factor: 9.427

Review 9.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

10.  Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus.

Authors:  Bruce D Greenwald; John A Dumot; J David Horwhat; Charles J Lightdale; Julian A Abrams
Journal:  Dis Esophagus       Date:  2009-06-09       Impact factor: 3.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.